News

Articles

Gilead and MacroGenics will work together on bispecific antibodies for the treatment of blood cancers.

Gilead and MacroGenics Enter $1.7 Billion Oncology Collaboration

Merck has exercised a $250 million option with Moderna to jointly develop and commercialize cancer vaccine mRNA-4157/V940.

Merck and Moderna Enter $250 Million Cancer Vaccine Partnership

FDA amended its authorization for the Moderna and Pfizer-BioNTech bivalent booster vaccines to permit their use in children as young as five years old.

FDA Authorizes Bivalent COVID-19 Boosters for Children Ages Five and Older

Biogen has agreed to pay $900 million to settle federal and state claims that it paid kickbacks to physicians to encourage them to prescribe its drugs.

Biogen to Settle Kickbacks Lawsuit for $900 Million

Pfizer is set to supply global fund up to 6 million treatment courses of its COVID-19 oral treatment, PAXLOVID, for low-and-middle-income countries.

Pfizer to Supply up to 6 Million PAXLOVID Treatment Courses for Low-and-Middle-Income Countries

Novo Nordisk’s $1.1 billion acquisition of Forma Therapeutics is intended to expand its sickle cell and rare blood disorder portfolio.

Novo Nordisk to Acquire Forma Therapeutics for $1.1 Billion

FDA has issued an emergency use authorization for both the Pfizer-BioNTech and Moderna bivalent COVID-19 boosters.

FDA Authorizes Bivalent COVID-19 Boosters

The European Union publishes long-awaited changes to Annex 1. 

Revisions to Annex 1 Officially Published

Moderna is suing Pfizer and BioNTech for allegedly infringing on patents the company filed from 2010 to 2016.

Moderna Files Suit Against Pfizer and BioNTech

Anthony Fauci announced that he plans to step down as Director of the National Institute of Allergy and Infectious Diseases in December 2022.

Top News